In Reply We thank Dr Weir for his interest in our article.1 Although none of the individual trials showed statistically significant reduction in mortality except for ALBATROSS study,2 cumulative evidence supported the role of mineralocorticoid receptor antagonist (MRA) treatment in patients with acute ST-elevation myocardial infarction (STEMI) without heart failure or left ventricular ejection (LVEF) fraction greater than 40%. The findings of our meta-analysis are consistent with a recently published individual patient level analysis of 2 trials that evaluated MRA therapy in such patients.3 Although individual studies may be inconclusive, or show conflicting results, meta-analysis may help with cumulative analysis of available research in a topic of interest, which has been demonstrated in the past.4
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Dahal K, Modi K. Mineralocorticoid Receptor Antagonism Treatment for All Patients With ST-Segment Myocardial Infarction?—Reply. JAMA Intern Med. 2018;178(11):1567–1568. doi:10.1001/jamainternmed.2018.5964
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: